Physician profile
Eric Wayne Beck
NPI 1811976806
$2,378.31
in general payments reported to CMS, 2019-2025
16 companies · $22.68 in 2025
The $22.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $19.08 · 2021: $356 · 2022: $711 · 2023: $494 · 2024: $539 · 2025: $22.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,166.11 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $310.53 | 2021-2024 | Ubrelvy |
| Lilly USA, LLC | $260.49 | 2021-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $172.11 | 2019-2023 | Lokelma, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.22 | 2019-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $80.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $72.15 | 2022-2024 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $59.16 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $38.69 | 2021-2022 | |
| Intra-Sana Laboratories | $26.42 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Boston Scientific Corporation | $22.68 | 2025 | Wavewriter Alpha Prime 16 |
| Azurity Pharmaceuticals, INC. | $17.08 | 2024 | |
| Sumitomo Pharma America, INC. | $15.50 | 2024 | Gemtesa |
| Amarin Pharma, INC. | $13.42 | 2021 | |
| Phadia US INC. | $13.32 | 2024 | Immunocap |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.